



GP 1553

RECEIVED

APR 04 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Arlington, VA 22202, on the date appearing below.

By KS Rhodes ELI LILLY AND COMPANY Date 3-28-02

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PT#3

Applicant	:	Mark Laurence Brader)	
Serial No.	:	10/010,038)	
Filed	:	December 6, 2001)	Confirm. No.: 8529
For	:	INSOLUBLE INSULIN COMPOSITIONS)	Group Art Unit: 1653
Docket No.	:	X-11232B)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Arlington, VA 22202

Sir:

As a means of complying with the duty of disclosure, Applicant submits an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provide a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicant submits that no fee is required.

The present application is a continuation of application Ser. No. 09/761,903. Listed on the Form PTO-1449 as document CH are the pending claims for co-pending application Ser. No. 09/761,903. A copy of the pending claims for application Ser. No. 09/761,903 is provided herewith.

Application Ser. No. 09/761,903 is a divisional of application Ser. No. 09/177,685, which issued as U.S. Patent No. 6,268,335, which is listed on the PTO-1449 as document AC.

Applicant requests consideration of this information.

Respectfully submitted,



Grant E. Reed
Attorney for Applicant
Registration No. 41,264
Phone: 317-276-1664

Eli Lilly and Company
Patent Division/GER
Lilly Corporate Center
Indianapolis, IN 46285

March 27, 2002

RECEIVED

FORM PTO 1449 (modified)		Atty. Docket No. X-11232B		Serial No 10/010,038	
INFORMATION DISCLOSURE IN AN APPLICATION		Applicants Mark Laurence Brader		Filing Date December 6, 2001	
		Group 1653			

U.S. PATENT DOCUMENTS

Examiner Initial	Number	Date	Name	Class	Sub- class	Filing Date if Appropriate
AA	5,840,680	Nov. 24, 1998	Balschmidt	514	3	Dec. 11, 1996
AB	4,946,828	Aug. 7, 1990	Markussen	514	3	Jul. 20, 1987
AC	6,268,335	Jul. 31, 2001	Brader	514	3	Oct. 22, 1998
AD	5,750,497	May 12, 1998	Havelund, et al.	514	3	Mar. 8, 1995
AE	6,011,007	Jan. 4, 2000	Havelund, et al.	514	3	Nov. 20, 1997
AF	3,868,357	Feb. 25, 1975	Smyth, et al.	260	112.7	Jan. 26, 1972
AG	2,849,370	Aug. 26, 1958	Petersen, et al.	167	75	May 28, 1954
AH	3,060,093	Oct. 23, 1962	Poulsen, et al.	167	75	Jul. 15, 1958
AI	3,864,325	Feb. 4, 1975	Smyth	260	112.7	Nov. 13, 1972
AJ	3,868,356	Feb. 25, 1975	Smyth	260	112.7	Jan. 26, 1972
AK	3,869,437	Mar. 4, 1975	Lindsay, et al.	260	112.7	Aug. 21, 1973
AL	3,950,517	Apr. 13, 1976	Lindsay, et al.	424	178	Dec. 6, 1974
AM	5,461,031	Oct. 24, 1995	DeFelippis	514	4	Jun. 16, 1994
AN	5,547,930	Aug. 20, 1996	Balschmidt	514	3	Sep. 28, 1993
AO	5,650,486	Jul. 22, 1997	DeFelippis	530	305	Jun. 1, 1995
AP	5,747,642	May 5, 1998	DeFelippis	530	304	Jun. 1, 1995
AQ	4,959,351	Sep. 25, 1990	Grau	514	4	Jul. 27, 1984
AR	5,948,751	Sep. 7, 1999	Kimer, et al.	514	4	Jun. 19, 1997
AS	6,127,334	Oct. 3, 2000	Kimer, et al.	514	3	Nov. 24, 1998
AT	6,051,551	Apr. 18, 2000	Hughes, et al.	514	3	Oct. 29, 1998
AU	6,335,316	Jan. 1, 2002	Hughes, et al.	514	3	Mar. 10, 2000

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO 1449 (modified)		Atty. Docket No. X-11232B		Serial No 10/010,038				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Mark Laurence Brader						
		Filing Date December 6, 2001		Group 1653				
FOREIGN PATENT DOCUMENTS								
		Document Number	Date	Country	Class	Sub- class	Translation	
							yes	no
	BA	EP 0375437	27 Jun 1990	EP				
	BB	WO 95/00550	05 Jan 1995	WIPO				
	BC	WO 95/07931	23 Mar 1995	WIPO				
	BD	WO 98/34953	13 Aug 1998	WIPO				
	BE	WO 96/29344	26 Sep 1996	WIPO				
	BF	WO 97/48413	24 Dec 1997	WIPO				
OTHER DOCUMENTS								
	CA		Fullerton, W. Wardle, et al., "Insulin Crystallization in the Presence of Basic Proteins and Peptides", <i>Biochim. Biophys. Acta</i> , 214:141-147 (1970), Elsevier Science, Amsterdam, The Netherlands					
	CB		Scott and Fisher, "Studies on Insulin With Protamine", <i>J. Pharmacol. Exp. Ther.</i> , 58:78-92 (May 1936), American Society for Pharmacology and Experimental Therapeutics, Bethesda, MD					
	CC		Hagedorn, et al., "Protamine Insulinate", <i>J. Am. Med. Assn.</i> , 106:177-180 (1936), American Medical Association, Chicago, IL					
	CD		Krayenbuhl and Rosenberg, "Crystalline Protamine Insulin", in: <i>Rep. Steno. Mem. Hosp. Nor. Insulinlab.</i> , 1:60-73 (1946), Copenhagen, Denmark					
	CE		Myers, S.R., et al., "Acylation of Human Insulin With Palmitic Acid Extends the Time Action of Human Insulin in Diabetic Dogs", <i>Diabetes</i> , 46:637-642 (April 1997), American Diabetes Association, Alexandria, VA					
	CF		Hashimoto, M., et al., "Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities", <i>Pharmaceut. Res.</i> , 6:171-176 (1989), American Association of Pharmaceutical Scientists, Arlington, VA					
	CG		Whittingham, et al., "Crystal Structure of Prolonged-Acting Insulin with Albumin-Binding Properties", <i>Biochemistry</i> , Vol. 36, No. 10, pages 2826-2831 (March 1997), American Chemical Society, Washington, DC					
	CH		Pending claims 110-162 for U.S. Application No. 09/761,903					
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								

RECEIVED
 APR 04 2002
 TECH CENTER 1600/2910